Lilly’s once‑daily pill posts late‑stage successes. Here’s what the data really say, how it stacks up against rivals, and what to expect on price, coverage, and patient experience.

Novo Nordisk faced critical leadership changes and mounting challenges from Pharmacy Benefit Managers (PBMs) amid fierce competition in the obesity drug market. With a new CEO recently appointed, the company is also doubling down on strategic partnerships in China, aiming to innovate its research pipeline. However, questions remain about the global acceptance of clinical data from these collaborations and the sustainability of Novo’s market position.

The “Research Use Only” Peptide Market Isn’t Slowing Down—It’s Evolving

Novo Nordisk ousted its longtime CEO just two weeks after scoring a major win with CVS Caremark, which named Wegovy its preferred weight-loss drug and dropped Eli Lilly’s Zepbound. But Lilly isn’t flinching. CEO David Ricks dismissed the move as “last decade,” signaling a shift away from exclusive PBM deals and toward direct-to-consumer access. As manufacturers double down on digital pharmacies and price cuts, the real fight for the obesity market may be happening outside the

Experimental weight loss drugs are being sold online for "research use only"—but many are injecting them at home.

Novo Nordisk just announced Wegovy for $499/month on its direct-to-consumer platform—but is this price cut really a game-changer?

Explore Medicare's groundbreaking decision to negotiate Ozempic pricing in PoundsPunch Periodical 2025.01.

Weight-Loss Drug Wars Heat Up, PBM Reform Stalls, and Insurers Push Back

Biden’s Weight-Loss Drug Proposal Faces Trump-Era Challenges, Ireland’s Crackdown on Counterfeits, and China’s Next-Gen GLP-1 Innovations

Caremark, Express Scripts, and OptumRx Face Allegations of Rigging the Rebate System

New Proposal to Expand Medicare Coverage Raises Questions on Cost and Potential Savings

Medicare’s Lower Drug Premiums, Lilly’s Shortage Supply Resolved While Compounding Pharmacies Still in Play

A Heated Exchange on the Super Star Weight Loss Drugs' Price, Big Pharma and PBM's Finger-Pointing Game

Commercial Insurance Dominated Weight Loss Prescriptions, Medicare May Target Wegovy for Price Cuts, FDA Reported Eased Drug Shortages